Sexual function is based on myriad factors, including psychological and physical components, such as libido, erection, orgasm and ejaculation.1,2 The obstructive and irritative symptoms that occur in BPH can compromise overall health and quality of life (QOL) and have a deleterious impact on sexuality and sexual function.3
Additionally, sexual dysfunction increases with age as does the prevalence of BPH.1,3 In fact, the Multinational Survey of the Aging Male (MSAM-7) study found that erectile dysfunction (ED) was associated with both increasing age and increasing severity of LUTS.3
Clinical studies demonstrate that a decrease in BPH symptoms results in improved QOL, libido and erectile function.3,4
Important Safety Information
FLOMAX is indicated to treat the signs and symptoms of benign prostatic hyperplasia (BPH). FLOMAX is not indicated to treat hypertension. As with other alpha-adrenergic blocking agents, there is a potential risk of syncope. Patients beginning treatment with FLOMAX should be cautioned to avoid driving or hazardous tasks for 12 hours after their first dose or increase in dose should syncope occur. The most common side effects are dizziness, abnormal ejaculation, and rhinitis.
Caution should be exercised with concomitant administration of warfarin and FLOMAX. In addition, FLOMAX should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. FLOMAX is contraindicated in patients known to be hypersensitive to tamsulosin HCl or any component of FLOMAX.
Before prescribing FLOMAX, please see the full Prescribing Information.
1. Guay AT, Spark RF, Bansal S, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple�s problem - 2003 update. Endocr Pract. 2003;9:77-95.
2. Gerber GS, Brendler CB. Evaluation of the urologic patient: history, physical examination, and urinalysis. In: Campbell MF, Walsh PC, Retik AB, eds. Campbell's Urology. 8th ed. Philadelphia, Pa: WB Saunders Co; 2002:83-110.
3. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol. 2003;44:637-649.
4. Höfner K, Claes H, De Reijke TM, et al, for the European Tamsulosin Study Group. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999;36:335-341.
